Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

- Have had a history of moderate to severe plaque psoriasis for at least 6 months prior
to Visit 1;

- Subjects with moderate to severe plaque psoriasis covering ≥10% body surface area
(BSA), with a psoriasis area and severity index (PASI) ≥12 and static Physician's
Global Assessment (sPGA) score ≥3 at Visit 1 and Visit 2

Exclusion Criteria:

- History of discontinuation of biologic therapies (including marketed and
investigational drugs) directly targeting Interleukin (IL)-17A, IL-17A/F, IL-17
receptor A, IL-12/IL-23p40 or IL-23p19 due to lack of efficacy, according to the
Investigator's judgment;

- Prior exposure to retinoid-related orphan receptor (ROR)-γ inhibitors;

- Presence of erythrodermic psoriasis, pustular psoriasis, guttate psoriasis,
medication-induced psoriasis or other skin conditions (e.g., clinically-significant
eczema or severe acne) at Visit 1;

- History or presence of itch due to underlying conditions other than plaque psoriasis
which cause or influence pruritus of the skin within 12 months prior to Visit 1.